Trials Sponsors Conditions Drugs Pricing

Conditions

Hidradenitis Suppurativa

Keywords

Hidradenitis SuppurativaAcne InversaAcitretin

Outcome Measures

Primary Outcomes (1)

Treatment Efficacy
Treatment efficacy will be assessed as the proportion of participants achieving a reduction of at least 5 points from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4) after 12 weeks of treatment.
12 weeks

Secondary Outcomes (1)

Change in International Hidradenitis Suppurativa Severity Score System (IHS4) Score
Baseline and 12 weeks

Study Arms (2)

Oral Apremilast Treatment

EXPERIMENTAL

Participants received oral apremilast 30 mg twice daily for 12 weeks.

Drug: Apremilast

Oral Acitretin Treatment

ACTIVE COMPARATOR

Participants received oral acitretin 25 mg twice daily for 12 weeks.

Drug: Acitretin

Interventions

ApremilastDrug

Oral apremilast 30 mg administered twice daily for 12 weeks in participants with moderate-to-severe hidradenitis suppurativa

Oral Apremilast Treatment

AcitretinDrug

Oral acitretin 25 mg administered twice daily for 12 weeks in participants with moderate-to-severe hidradenitis suppurativa

Oral Acitretin Treatment

Eligibility Criteria

Age18 Years - 40 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

Adults aged 18 to 40 years.
Clinically diagnosed moderate hidradenitis suppurativa (International

Sponsors & Collaborators

Hayat Abad Medical Complex, Peshawar
Governmentlead

Study Sites (1)

Medical Teaching Institution-Lady Reading Hospital

Peshawar, Khyber Pakhtunkhwa, 26000, Pakistan

MeSH Terms

Conditions

Hidradenitis Suppurativa

Interventions

apremilastAcitretin

Condition Hierarchy (Ancestors)

Skin Diseases, BacterialBacterial InfectionsBacterial Infections and MycosesInfectionsSkin Diseases, InfectiousSuppurationSkin DiseasesSkin and Connective Tissue DiseasesHidradenitisSweat Gland Diseases

Intervention Hierarchy (Ancestors)

Enrollment

70 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 4
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER GOV
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: PGR

Study Record Dates

First Submitted

July 13, 2026

First Posted

July 16, 2026

Study Start

Comparative Efficacy of Apremilast and Acitretin in Moderate-to-Severe Hidradenitis Suppurativa

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Oral Apremilast Treatment

Oral Acitretin Treatment

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

Oral Apremilast Treatment

Oral Acitretin Treatment

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations